Nuvectis Pharma (NVCT) Change in Account Payables (2023 - 2026)

Nuvectis Pharma has disclosed Change in Account Payables across 4 years of filings, most recently posting -$1.6 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$1.6 million, down 419.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (up 38.12% YoY), and the FY2025 annual result was $3.8 million, up 1483.15% from the prior year.
• Change in Account Payables came in at -$1.6 million for Q1 2026 at Nuvectis Pharma, down from -$165000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.0 million in Q2 2025 to a low of -$1.6 million in Q1 2026.
• The 4-year median for Change in Account Payables is $87000.0 (2024), against an average of $137307.7.
• Across the five-year window, Change in Account Payables soared 2181.61% in 2025 and slumped 419.64% in 2026, its largest moves.
• Nuvectis Pharma's Change in Account Payables stood at -$721000.0 in 2023, then surged by 132.87% to $237000.0 in 2024, then plunged by 169.62% to -$165000.0 in 2025, then slumped by 856.97% to -$1.6 million in 2026.
• The last three Change in Account Payables figures came in at -$1.6 million (Q1 2026), -$165000.0 (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.